Vivani Medical shares are trading higher after the company announced the FDA cleared the Investigational New Drug Application and lifted the clinical hold on NPM-119.

6/13/24 8:08:48 AM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $VANI alert in real time by email

Get the next $VANI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VANI

Date	Price Target	Rating	Analyst

More analyst ratings

$VANI
Press Releases

Fastest customizable press release news feed in the world

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
Regulatory approval to initiate first-in-human study with a miniature, ultra long-acting GLP-1 (exenatide) implant in obese or overweight individuals in Australia Miniature, ultra long-acting GLP-1 implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Announces $5M equity financing which secures solid financial position into late 2025, supporting projected completion of first-in-human study and data read-out Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for t
11/13/24 8:30:00 AM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now
MIAMI, Oct. 30, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsor:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) [email protected]
10/30/24 7:00:00 AM ET
$AEMD
$ASPI
$BNRG
$CIA
Medical/Dental Instruments
Health Care
Major Chemicals
Industrials
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@Quote
10/29/24 7:00:00 AM ET
$AEMD
$ASPI
$BNRG
$CIA
Medical/Dental Instruments
Health Care
Major Chemicals
Industrials

Vivani Medical shares are trading higher after the company announced the FDA cleared the Investigational New Drug Application and lifted the clinical hold on NPM-119.

Chat with this insight

Recent Analyst Ratings for
$VANI

$VANI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Williams Gregg bought $4,999,999 worth of shares (3,968,253 units at $1.26), increasing direct ownership by 545% to 4,695,861 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $2,835 worth of shares (2,500 units at $1.13), increasing direct ownership by 5% to 50,000 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $11,120 worth of shares (9,000 units at $1.24), increasing direct ownership by 23% to 47,500 units (SEC Form 4)

$VANI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

SEC Form SC 13D filed by Vivani Medical Inc.

$VANI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Williams Gregg bought $4,999,999 worth of shares (3,968,253 units at $1.26), increasing direct ownership by 545% to 4,695,861 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $2,835 worth of shares (2,500 units at $1.13), increasing direct ownership by 5% to 50,000 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $11,120 worth of shares (9,000 units at $1.24), increasing direct ownership by 23% to 47,500 units (SEC Form 4)

$VANI
SEC Filings

$VANI
Market Insights

Live Market Insights

SEC Form 10-Q filed by Vivani Medical Inc.

Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Vivani Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

EXCLUSIVE: Vivani Tells Benzinga 'The NPM-115 clinical program will consist of a series of studies designed to support the development of Vivani's miniature, 6-month GLP-1 NanoPortalTM implant for chronic weight management in obese or overweight patients'

EXCLUSIVE: Vivani Medical Tells Benzinga 'Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024'

EXCLSUIVE: Vivani Medical Tells Benzinga Co. Provides Update On Clinical Development Plans For Miniature, Long-Term, GLP-1 Obesity Implant Program, NPM-115

$VANI
Press Releases

Fastest customizable press release news feed in the world

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Vivani Medical shares are trading higher after the company announced the FDA cleared the Investigational New Drug Application and lifted the clinical hold on NPM-119.

Chat with this insight

Recent Analyst Ratings for $VANI

$VANI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Williams Gregg bought $4,999,999 worth of shares (3,968,253 units at $1.26), increasing direct ownership by 545% to 4,695,861 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $2,835 worth of shares (2,500 units at $1.13), increasing direct ownership by 5% to 50,000 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $11,120 worth of shares (9,000 units at $1.24), increasing direct ownership by 23% to 47,500 units (SEC Form 4)

$VANI Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

SEC Form SC 13D filed by Vivani Medical Inc.

$VANI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Williams Gregg bought $4,999,999 worth of shares (3,968,253 units at $1.26), increasing direct ownership by 545% to 4,695,861 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $2,835 worth of shares (2,500 units at $1.13), increasing direct ownership by 5% to 50,000 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $11,120 worth of shares (9,000 units at $1.24), increasing direct ownership by 23% to 47,500 units (SEC Form 4)

$VANI SEC Filings

$VANI Market Insights

Live Market Insights

SEC Form 10-Q filed by Vivani Medical Inc.

Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Vivani Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

EXCLUSIVE: Vivani Tells Benzinga 'The NPM-115 clinical program will consist of a series of studies designed to support the development of Vivani's miniature, 6-month GLP-1 NanoPortalTM implant for chronic weight management in obese or overweight patients'

EXCLUSIVE: Vivani Medical Tells Benzinga 'Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024'

EXCLSUIVE: Vivani Medical Tells Benzinga Co. Provides Update On Clinical Development Plans For Miniature, Long-Term, GLP-1 Obesity Implant Program, NPM-115

$VANI Press Releases

Fastest customizable press release news feed in the world

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Recent Analyst Ratings for
$VANI

$VANI
Insider Purchases

$VANI
Large Ownership Changes

$VANI
Insider Trading

$VANI
SEC Filings

$VANI
Market Insights

$VANI
Press Releases